A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors (Q36027379)

11 August 2017

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors (English)

1 reference

11 August 2017

phase II clinical trial

0 references

author name string

J R Strosberg

1

1 reference

11 August 2017

J M Weber

2

1 reference

11 August 2017

J Choi

3

1 reference

11 August 2017

T L Campos

4

1 reference

11 August 2017

T L Valone

5

1 reference

11 August 2017

G Han

6

1 reference

11 August 2017

M J Schell

7

1 reference

11 August 2017

L K Kvols

8

1 reference

11 August 2017

8 February 2012

1 reference

11 August 2017

1 reference

11 August 2017

23

1 reference

11 August 2017

9

1 reference

11 August 2017

2335-2341

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Molecular basis for sunitinib efficacy and future clinical development

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Transcatheter chemoembolization of progressive carcinoid liver metastasis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Cytoreductive hepatic surgery for neuroendocrine tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Karnofsky memorial lecture. An odyssey in the land of small tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559904

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

23 September 2018

1 reference

12 December 2020

Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival

1 reference

12 December 2020

Hepatic resection for metastatic neuroendocrine carcinomas

1 reference

12 December 2020

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

12 December 2020

Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization

1 reference

12 December 2020

Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression

1 reference

12 December 2020

Aggressive surgery for metastatic liver neuroendocrine tumors

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDR614

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22317769

1 reference